Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The world's largest clinical trial to see whether taking a daily dose of aspirin can stop cancer from recurring has been launched in the UK.
Subscribe to our email newsletter
The Add-Aspirin phase III trial is funded by Cancer Research UK and the National Institute for Health Research.
It aims is to establish whether taking aspirin every day for five years can stop or delay cancers that have been caught and treated at an early stage from coming back.
The trial will be carried out on 11,000 patients who have recently had or are having treatment for bowel, breast, oesophagus, prostate or stomach cancer.
It will run at over 100 centers across the UK and will last for about 12 years. The study will compare a group of people taking either 300mg or 100mg of aspirin daily and a group taking dummy drugs.
Cancer Research UK head of population research Fiona Reddington said: "Aspirin’s possible effects on cancer are fascinating and we hope this trial will give us a clear answer on whether or not the drug helps stop some cancers coming back.
"This trial is especially exciting as cancers that recur are often harder to treat so finding a cheap and effective way to prevent this is potentially game-changing for patients."
Image: The Add-Aspirin phase III trial will run at over 100 centers across the UK. Photo: courtesy of Cancer Research UK.